Altimmune (ALT) Enterprise Value (2010 - 2026)

Altimmune (ALT) has 17 years of Enterprise Value data on file, last reported at -$331.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 574.11% year-over-year to -$331.6 million in Q1 2026; TTM through Mar 2026 was -$331.6 million, a 574.11% decrease from a year earlier, with the FY2025 full-year figure at -$43.8 million, down 18.47% from the prior year.
• Enterprise Value for Q1 2026 stood at -$331.6 million, down from -$43.8 million in the prior quarter.
• Over the last five years, Enterprise Value for ALT reached as high as -$37.0 million in Q4 2024 and fell as low as -$331.6 million in Q1 2026.
• Historically, Enterprise Value has averaged -$128.9 million across 5 years, with a median of -$111.2 million in 2022.
• Across the five-year window, Enterprise Value surged 72.98% in 2025 and slumped 574.11% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$111.2 million in 2022, then fell by 21.62% to -$135.2 million in 2023, then surged by 72.63% to -$37.0 million in 2024, then decreased by 18.47% to -$43.8 million in 2025, then plunged by 656.28% to -$331.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$331.6 million in Q1 2026, -$43.8 million in Q4 2025, and -$61.3 million in Q3 2025.